Abstract 230 - IMPIEGO DEI GLICOPEPTIDI NELLA ... - SIMIT

146
10° CONGRESSO NAZIONALE SIMIT
Abstract 16
- SWIFT STUDY: SWITCHING FROM LAMIVUDINE/ABACAVIR (3TC/ABC) TO
EMTRICITABINE/TENOFOVIR DF (FTC/TDF) IMPROVED FASTING LIPID
PARAMETERS WHILE MAINTAINING VIROLOGIC SUPPRESSION -
Dejesus E. [2] , Campo R. E. [3] , Bredeeck F. [4] , Wang H. [1] , Dau L. [1] , Picaro L. A.* [1]
- [1] Gilead Sciences ~ Foster City - USA - [2] Orlando Immunology Center ~ Orlando - [3] Division of Infectious Diseases,
University of Miami ~ Miami - [4] Metropolis Medical School ~ San Francisco
INFEZIONI DA HIV
Premessa: In prior treatment naïve and experienced studies, use of TDF has been
associated with more favorable lipid profile. There are limited data on the impact of
switching from fixed-dose 3TC/ABC to FTC/TDF, particularly in older HIV+ subjects.
Obiettivo: Prospective, multicenter, randomized 48 week study to evaluate the safety and
efficacy of switching subjects from 3TC/ABC to FTC/TDF. Subjects receiving 3TC/ABC +
PI/r with HIV RNA < 200c/mL ? 3 months were randomized (1:1) to either continue
3TC/ABC or switch to FTC/TDF, with PI/r unchanged. Subjects were stratified by PI/r
(LPV/r vs. other) and co-morbidities (CV disease, DM, hyperlipidemias). Fasting lipid
profile and 10 year Framingham scores were evaluated though Week 48.
Risultati: 311 subjects were treated (FTC/TDF 155, 3TC/ABC 156). Baseline
characteristics were similar between arms: 85% males, median age 46 years, 72% with
comorbidities, and 47% taking lipid-lowering agents. No differences in early
discontinuation rates (11%) or percents of subjects with adverse events were observed
between arms. Through Week 48, FTC/TDF was non-inferior to 3TC/ABC by TLOVR
(86.5% vs 83.3% HIV RNA